Table 5.
Strata | G1m genotype a | number | Baseline DAS28 | ΔDAS28 | Beta b | P-value b | R c | NR c | OR b | P-value b |
---|---|---|---|---|---|---|---|---|---|---|
All patients | G1m1,17+ | 523 | 6.3 ± 1.1 | 2.3 ± 1.4 | 0.09 | 0.002 | 153 (29.3) | 79 (15.1) | 1.5 | 0.035 |
G1m1,17- | 429 | 6.2 ± 1.2 | 2.0 ± 1.5 | 98 (22.8) | 90 (21.0) | |||||
INX | G1m1,17+ | 387 | 6.3 ± 1.1 | 2.3 ± 1.5 | 0.11 | 0.001 | 116 (30.0) | 67 (17.3) | 1.5 | 0.03 |
G1m1,17- | 314 | 6.2 ± 1.3 | 1.9 ± 1.5 | 67 (21.3) | 78 (24.8) | |||||
ADM | G1m1,17+ | 136 | 6.2 ± 1.1 | 2.5 ± 1.4 | 0.03 | 0.55 | 37 (27.2) | 12 (8.8) | 1.1 | 0.57 |
G1m1,17- | 115 | 6.2 ± 1.2 | 2.5 ± 1.4 | 31 (27.0) | 12 (10.4) |
aCarrier status; banalyses adjusted for baseline DAS28 and gender (and anti-TNF for All patients); cnumber (% response class/all patients with this genotype). ADM, adalimumab; DAS28, disease activity score in 28 joints; IFX, infliximab; NR, non-responders; R, responders.